In this issue:
Broad rim lesions as a potential biomarker for rapid MS progression
Asymptomatic T2 hyperintense cervical spinal cord lesions in RRMS
Suboptimal B-cell depletion & PIRA with ocrelizumab
Earlier age of MS onset & diagnosis in Asian patients
KFLC-index to differentiate MS from other inflammatory demyelinating diseases
Natalizumab vs. anti-CD20 therapies in RRMS
Natalizumab vs. interferon β-1a in SPMS
POINT: ponesimod + DMF in relapsing MS
Elezanumab + standard of care in relapsing/progressive MS
Prognostic biomarkers for MS in RIS
Please login below to download this issue (PDF)